Ralliant Corporation $RAL Shares Sold by Y Intercept Hong Kong Ltd

Y Intercept Hong Kong Ltd cut its position in shares of Ralliant Corporation (NYSE:RAL) by 54.3% in the first quarter, HoldingsChannel.com reports. The institutional investor owned 47,423 shares of the company’s stock after selling 56,399 shares during the quarter. Y Intercept Hong Kong Ltd’s holdings in Ralliant were worth $1,972,000 at the end of the most recent quarter.

A number of other institutional investors have also modified their holdings of the company. Cetera Investment Advisers purchased a new position in shares of Ralliant during the second quarter valued at approximately $700,000. Russell Investments Group Ltd. purchased a new stake in Ralliant in the 2nd quarter worth approximately $1,465,000. EverSource Wealth Advisors LLC purchased a new stake in Ralliant in the 2nd quarter worth approximately $39,000. First Trust Advisors LP purchased a new stake in Ralliant in the 2nd quarter worth approximately $2,013,000. Finally, Federated Hermes Inc. acquired a new position in Ralliant in the 2nd quarter valued at $326,000.

Analyst Ratings Changes

A number of research analysts have weighed in on RAL shares. Truist Financial reissued a “buy” rating and set a $68.00 price target (up from $53.00) on shares of Ralliant in a research note on Wednesday, May 13th. Wall Street Zen lowered Ralliant from a “buy” rating to a “hold” rating in a research note on Sunday, June 28th. Morgan Stanley increased their target price on Ralliant from $68.00 to $85.00 and gave the stock an “overweight” rating in a research report on Tuesday, June 23rd. Citigroup raised their price target on Ralliant from $51.00 to $70.00 and gave the stock a “buy” rating in a research note on Wednesday, May 13th. Finally, Evercore began coverage on Ralliant in a report on Tuesday, June 9th. They issued an “outperform” rating and a $80.00 price target for the company. One research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, three have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $69.00.

Ralliant Stock Up 0.7%

Shares of Ralliant stock opened at $68.22 on Thursday. The company has a fifty day moving average price of $62.02 and a 200 day moving average price of $52.32. The company has a current ratio of 1.61, a quick ratio of 1.05 and a debt-to-equity ratio of 0.73. Ralliant Corporation has a twelve month low of $37.27 and a twelve month high of $75.41. The stock has a market cap of $7.64 billion and a price-to-earnings ratio of -6.24.

Ralliant (NYSE:RAL) last released its quarterly earnings data on Tuesday, May 12th. The company reported $0.57 EPS for the quarter, beating the consensus estimate of $0.49 by $0.08. Ralliant had a positive return on equity of 12.49% and a negative net margin of 58.55%.The company had revenue of $534.60 million for the quarter. Ralliant’s revenue was up 11.0% compared to the same quarter last year. Ralliant has set its FY 2026 guidance at 2.530-2.690 EPS and its Q2 2026 guidance at 0.580-0.640 EPS. Equities research analysts forecast that Ralliant Corporation will post 2.64 earnings per share for the current fiscal year.

Ralliant Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Tuesday, June 23rd. Stockholders of record on Monday, June 8th were paid a $0.05 dividend. The ex-dividend date was Monday, June 8th. This represents a $0.20 dividend on an annualized basis and a dividend yield of 0.3%. Ralliant’s dividend payout ratio (DPR) is -1.83%.

Ralliant Company Profile

Ralliant, Inc (NYSE: RAL) is a medical technology company focused on enabling point-of-care cell therapy solutions in the field of regenerative medicine. The company develops and markets systems that isolate, concentrate and store adipose-derived stromal vascular fraction (SVF) cells directly from a patient’s own fat tissue, facilitating same-day, autologous treatments without the need for extensive laboratory infrastructure.

The company’s core product portfolio includes proprietary device platforms and single-use processing kits engineered to streamline the workflow for clinicians.